LONA
LeonaBio, Inc. NASDAQ Listed Sep 18, 2020$8.27
Mkt Cap $35.4M
52w Low $2.95
60.9% of range
52w High $11.68
50d MA $9.21
200d MA $6.44
P/E (TTM)
—
EV/EBITDA
—
P/B
1.3x
Debt/Equity
0.0x
ROE
-380.0%
P/FCF
-0.8x
RSI (14)
32.80
ATR (14)
$0.58
Beta
2.23
50d MA
$9.21
200d MA
$6.44
Avg Volume
32.7K
LeonaBio, Inc., clinical-stage biopharmaceutical company, focuses on developing small molecules to restore neuronal health and slow neurodegradation. Its product pipeline includes ATH-1105 for the treatment of amyotrophic lateral sclerosis, which is in phase 1 clinical trial; ATH-1020 for the treatment of neurodegenerative diseases, which is phase 1 clinical trial, as well as early compounds which is in preclinical phase. The company was formerly known as Athira Pharma, Inc. and changed its name to LeonaBio, Inc. in January 2026. LeonaBio, Inc. was incorporated in 2011 and is headquartered in Bothell, Washington.
18706 North Creek Parkway · Bothell, WA 98011 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| May 7, 2026 | AMC | -2.28 | -1.73 | +24.0% | 9.86 | -0.1% | +1.8% | -0.3% | +1.6% | +1.5% | +6.6% | — |
| Mar 26, 2026 | AMC | -1.35 | -18.92 | -1300.3% | 9.68 | -8.2% | -7.3% | +3.3% | +10.9% | -2.5% | +13.3% | — |
| Nov 6, 2025 | AMC | -1.06 | -1.68 | -58.5% | 4.01 | -1.5% | -4.0% | +19.0% | +1.1% | +1.5% | +0.0% | — |
| Aug 7, 2025 | AMC | -1.80 | -1.80 | +0.0% | 3.70 | +4.1% | +5.9% | -3.1% | +1.3% | +1.3% | +2.1% | — |
| May 9, 2025 | AMC | -0.20 | -0.23 | -15.0% | 2.54 | +13.0% | +6.3% | +3.7% | -7.1% | +7.3% | -2.5% | — |
| Feb 27, 2025 | AMC | -0.23 | -0.39 | -69.6% | 4.23 | -3.1% | -2.8% | -8.5% | -0.5% | +1.3% | -7.7% | — |
| Nov 7, 2024 | AMC | -0.80 | -0.75 | +6.2% | 7.50 | -4.7% | -12.0% | -2.0% | +23.6% | -8.8% | -2.2% | — |
| Aug 1, 2024 | AMC | -0.75 | -0.70 | +6.7% | 32.50 | -0.9% | -1.2% | -1.9% | +0.0% | -1.6% | -1.0% | — |
| May 15, 2024 | AMC | -0.80 | -0.69 | +13.8% | 22.10 | +5.9% | +22.6% | -7.0% | +0.0% | +0.8% | +3.1% | — |
| Feb 22, 2024 | AMC | -0.96 | -0.71 | +26.0% | 39.30 | +1.8% | +0.0% | -0.5% | +2.6% | -1.0% | -3.0% | — |
| Nov 9, 2023 | AMC | -0.87 | -0.87 | +0.0% | 13.90 | +7.9% | +6.5% | +5.4% | -2.6% | +4.6% | -0.6% | — |
| Aug 10, 2023 | AMC | -0.81 | -0.78 | +3.7% | 30.30 | -0.3% | -7.3% | -0.4% | -4.6% | -0.7% | -1.1% | — |
| May 11, 2023 | AMC | -0.66 | -0.73 | -10.6% | 29.50 | +0.0% | +0.0% | -2.7% | -5.6% | +1.8% | +2.9% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| May 27 | Piper Sandler | Initiates | Overweight | $20 | $9.67 | $10.00 | +3.4% | +1.4% | -1.7% | -1.0% | -2.6% | -1.8% |
| Feb 19 | Mizuho | Upgrade | Neutral → Outperform | — | $4.76 | $5.12 | +7.6% | +16.2% | +0.5% | +4.3% | +2.4% | -2.2% |
| Aug 10 | JMP Securities | Maintains | Outperform → Outperform | — | $28.80 | $28.90 | +0.3% | +5.2% | -7.3% | -0.4% | -4.6% | -0.7% |
| May 14 | Mizuho | Maintains | Buy → Buy | — | — | — | — | — | — | — | — | — |
| Mar 29 | BTIG | Maintains | Buy → Buy | — | $22.60 | $22.80 | +0.9% | +4.9% | +3.8% | +1.6% | +0.8% | -2.8% |
| Mar 24 | JMP Securities | Maintains | Market Outperform → Outperform | — | $24.00 | $23.60 | -1.7% | +2.1% | -3.3% | -4.6% | +4.9% | +3.8% |
| Jul 7 | Mizuho | Maintains | Buy → Buy | — | $33.90 | $35.00 | +3.2% | +9.4% | +1.3% | -11.4% | -1.2% | +3.3% |
| Jun 22 | Jefferies | Downgrade | Buy → Hold | — | $84.50 | $26.40 | -68.8% | -66.3% | -3.5% | -0.4% | +4.0% | -2.1% |
| Jun 22 | JMP Securities | Downgrade | Market Outperform → Market Perform | — | $84.50 | $26.40 | -68.8% | -66.3% | -3.5% | -0.4% | +4.0% | -2.1% |
| Jun 22 | Stifel | Downgrade | Buy → Hold | — | $84.50 | $26.40 | -68.8% | -66.3% | -3.5% | -0.4% | +4.0% | -2.1% |
| May 10 | BTIG | Maintains | Buy → Buy | — | $88.40 | $93.30 | +5.5% | +4.9% | -9.2% | -5.5% | +4.0% | +4.7% |
| Apr 21 | Berenberg | Maintains | Buy → Buy | — | $116.30 | $119.80 | +3.0% | +1.3% | -2.9% | -0.3% | -3.4% | -4.4% |
| Dec 15 | Goldman Sachs | Maintains | Neutral → Neutral | — | $134.10 | $132.10 | -1.5% | -3.2% | -8.0% | +2.9% | -1.9% | +3.1% |
No insider trades available.
8-K · 2.01
!!! Very High
Unknown — 8-K 2.01: Acquisition Completed
LONA completed an acquisition that could expand its asset base and revenue streams, making it potentially attractive to growth-focused investors seeking increased operational scale.
Mar 31
8-K · 7.01
! Medium
Unknown — 8-K 7.01: Regulation FD Disclosure
LONA disclosed its information distribution channels via Regulation FD, suggesting upcoming material announcements; investors should monitor these platforms for significant company developments affecting stock valuation.
Mar 26
8-K · 5.02
!!! Very High
Unknown — 8-K 5.02: Executive Change
LONA's new 2026 equity plan authorizing 5.7M shares dilutes existing shareholders but signals management confidence in long-term value creation through performance-based incentives.
Mar 19
Institutional (13F) — Top 19
All ↗
| # | Manager | Shares | Value | Chg | Period |
|---|---|---|---|---|---|
| 1 | Adar1 Capital Management, Llc | 727,481 | $7M | New | Mar 2026 |
| 2 | Kalehua Capital Management Llc | 393,701 | $4M | — | Mar 2026 |
| 3 | Vanguard Capital Management Llc | 194,760 | $2M | New | Mar 2026 |
| 4 | Propel Bio Management, Llc | 149,279 | $1M | — | Mar 2026 |
| 5 | Renaissance Technologies Llc | 64,222 | $660K | Reduced | Mar 2026 |
| 6 | Bank Of America Corp /de/ | 32,566 | $335K | — | Mar 2026 |
| 7 | Millennium Management | 31,678 | $326K | Reduced | Mar 2026 |
| 8 | Northern Trust Corp | 14,394 | $148K | Added | Mar 2026 |
| 9 | Two Sigma Investments, Lp | 13,276 | $136K | Added | Mar 2026 |
| 10 | Acadian Asset Management Llc | 10,230 | $105K | Reduced | Mar 2026 |
| 11 | Jane Street Group, Llc | 13,186 | $100K | New | Dec 2025 |
| 12 | Royal Bank Of Canada | 2,225 | $23K | Added | Mar 2026 |
| 13 | Ubs Group Ag | 1,299 | $13K | Reduced | Mar 2026 |
| 14 | Morgan Stanley | 940 | $7K | Reduced | Dec 2025 |
| 15 | American Capital Advisory, Llc | 200 | $2K | — | Mar 2026 |
| 16 | Mcilrath & Eck, Llc | 82 | $843 | New | Mar 2026 |
| 17 | Us Bancorp \de\ | 81 | $613 | — | Dec 2025 |
| 18 | Bnp Paribas Financial Markets | 23 | $236 | — | Mar 2026 |
| 19 | Jpmorgan Chase & Co | 12 | $111 | — | Mar 2026 |
Mutual Funds / ETFs (N-PORT) — Top 6
All ↗
| # | Fund | Shares | Value | Period |
|---|---|---|---|---|
| 1 | Fidelity Total Market Index Fund | 4,760 | $27K | Feb 2026 |
| 2 | Fidelity Series Total Market Index Fund | 3,932 | $22K | Feb 2026 |
| 3 | U.S. MICRO CAP PORTFOLIO | 3,774 | $18K | Jan 2026 |
| 4 | Dimensional US Core Equity 1 ETF | 2,614 | $12K | Jan 2026 |
| 5 | Fidelity Nasdaq Composite Index Fund | 659 | $4K | Feb 2026 |
| 6 | Guggenheim Active Allocation Fund | 19 | $107 | Feb 2026 |
Valuation
Market Cap
$35.4M
Enterprise Value
-$52.6M
P/E (TTM)
—
Forward P/E
—
PEG Ratio
0.15x
P/B
1.27x
P/S
—
P/FCF
-0.77x
EV/EBITDA
—
Shares Out
4.3M
Financials (TTM)
Revenue
$0
Net Income
-$129.4M
EBITDA
-$108.8M
Free Cash Flow
-$45.7M
Op Cash Flow
-$45.7M
EPS Basic
$-24.70
EPS Diluted
$-30.11
EPS Forward
$-4.57
Gross Margin
—
Op Margin
—
Net Margin
—
Balance Sheet
Total Assets
$92.2M
Total Liab.
$64.4M
Total Equity
$27.8M
Cash
$88.3M
LT Debt
$338K
Book Value/Sh
$6.50
Debt/Equity
0.03x
Current Ratio
1.88
Quick Ratio
1.88
Returns & Growth
ROE
-380.0%
ROA
-114.6%
ROIC
-226.7%
Rev Growth YoY
+0.0%
EPS Growth YoY
+2.0%
Price Returns
2W
-11.9%
1M
+6.5%
3M
+72.1%
6M
+122.8%
12M
+209.6%
Technicals
52W High
$11.68
52W Low
$2.95
50d MA
$9.21
200d MA
$6.44
RSI (14)
32.80
ATR (14)
$0.58
Beta
2.23
Avg Volume
33K
Dividends
Div Rate
$0.00
Div Yield
—
Frequency
—
Ex-Div Date
—
Analyst Price Targets
Consensus
$10.00
High
$10.00
Low
$10.00
Median
$10.00
Data updated apr 25, 2026 7:40pm
· Source: financialmodelingprep.com